Spruce Biosciences, Inc. (SPRB) Return on equity 2022–2025
Spruce Biosciences, Inc. (SPRB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-91.7%FY2025 · since FY2022: -67.4% → -91.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -91.7% | +92.4 pp |
| FY2024 | -184.0% | -121.4 pp |
| FY2023 | -62.6% | +4.8 pp |
| FY2022 | -67.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRB financial trends
SPRB RevenueSPRB Net incomeSPRB Net marginSPRB Gross profitSPRB Gross marginSPRB Operating incomeSPRB Operating marginSPRB Operating cash flowSPRB Free cash flowSPRB Capital expendituresSPRB Stock buybacksSPRB Dividends paidSPRB Total assetsSPRB Total liabilitiesSPRB Shareholders’ equitySPRB overview →